Quantcast
Channel: WN.com - Articles related to Aerie Pharmaceuticals Receives Positive Feedback from FDA
Browsing latest articles
Browse All 57 View Live

DelMar Pharmaceuticals Invited to Present at The World NSCLC Summit on June...

VANCOUVER, British Columbia and MENLO PARK, Calif., June 15, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on...

View Article



Adamas Announces Additional Findings From Its Phase 2/3 Trial of ADS-5102 for...

(Source: Adamas Pharmaceuticals Inc) EMERYVILLE, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced additional findings from its Phase 2/3 study...

View Article

DBV Technologies Confirms Planned Initiation of Viaskin® Peanut Global Phase...

(Source: DBV Technologies SA) Press Release Bagneux, France, June 23, 2015 DBV Technologies Confirms Planned Initiation of Viaskin® Peanut Global Phase III Clinical Trial in Children Following End-...

View Article

Anthera Pharmaceuticals Has Reached Enrollment Target in CHABLIS-SC1 Phase 3...

(Source: Anthera Pharmaceuticals Inc) HAYWARD, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has met the enrollment target of its...

View Article

Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in...

NEWTON, Mass. and JERUSALEM, June 15, 2015 /PRNewswire-USNewswire/ -- Chiasma, Inc., a U.S. privately held biopharma company, today announced the company has submitted a New Drug Application (NDA) to...

View Article


Ascletis as the First Chinese Company to File Clinical Applications for...

HANGZHOU, China, June 24, 2015 /PRNewswire/ -- Ascletis today announced that clinical trial applications for its interferon (IFN)-free regimen to treat chronic hepatitis C (CHC) have been filed and...

View Article

Tobira Therapeutics Announces Appointment of Ian Clements as Vice President,...

SOUTH SAN FRANCISCO, Calif., June 23, 2015 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...

View Article

AERIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered...

NEW YORK, NY--(Marketwired - June 24, 2015) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") (NASDAQ:...

View Article


Celator® Pharmaceuticals Announces Positive Induction Response Results from...

EWING, N.J., June 24, 2015 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced final induction response rate results (complete remission plus complete remission with incomplete...

View Article


Spectrum Pharmaceuticals Announces Publication of Beleodaq® Data Selected as...

(Source: Spectrum Pharmaceuticals Inc) Beleodaq is marketed in the U.S. by Spectrum Pharmaceuticals, Inc. HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology...

View Article

Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical...

SAN DIEGO, June 25, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the company's...

View Article

Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal...

CARLSBAD, Calif., June 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label,...

View Article

Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125...

VANCOUVER, British Columbia, June 25, 2015 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted...

View Article


AERI INVESTOR DEADLINE ALERT: Law Offices of Howard G. Smith Reminds...

Law Offices of Howard G. Smith reminds investors of Aerie Pharmaceuticals, Inc. (“Aerie Pharmaceuticals” or the “Company”) (NASDAQ: AERI), who purchased the Company’s securities between August 6, 2014...

View Article

Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical...

(Source: Conatus Pharmaceuticals Inc) SAN DIEGO, June 25, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced pre-treatment biomarker and histology data from the first...

View Article


Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of...

NEW YORK, June 25, 2015 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District...

View Article

Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal...

(Source: Isis Pharmaceuticals Inc) CARLSBAD, Calif., June 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on children with spinal muscular atrophy (SMA) who...

View Article


ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program...

(Source: ACADIA Pharmaceuticals Inc) ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson's Disease Psychosis at the 19th International...

View Article

GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation...

GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that Pfizer Inc. (NYSE: PFE) has dosed the first patient in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study – a Phase...

View Article

GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation...

(Source: GlycoMimetics Inc) GAITHERSBURG, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that Pfizer Inc. (NYSE: PFE) has dosed the first patient in the RESET (Rivipansel:...

View Article

Tokai Pharmaceuticals Announces Initiation of Phase 3 ARMOR3-SV Trial of...

(Source: Tokai Pharmaceuticals Inc) Tokai Pharmaceuticals Announces Initiation of Phase 3 ARMOR3-SV Trial of Galeterone in AR-V7 Positive Metastatic Castration-Resistant Prostate Cancer ARMOR3-SV...

View Article


Aerie sees stock jump 40% on good news from FDA

(Nasdaq: AERI), a drug developer with roots in , saw its market value jump more than 40 percent after hours Monday on good news from the U.S. Food and Drug Administration. To be sure, the company is...

View Article


(AERI) (ACUR) (COTY) Higher; (AAVL) (CPST) (TWTR) Lower (more...)

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) 48.7% HIGHER; reported that the U.S. Food and Drug Administration (FDA) has agreed in written and verbal communications that Aerie may change the primary...

View Article

(AERI) (SCTY) (UA) HIGHER; (AAVL) (PFIE) (TAHO) LOWER (more...)

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) 40.9% HIGHER; reported that the U.S. Food and Drug Administration (FDA) has agreed in written and verbal communications that Aerie may change the primary...

View Article

Aerie Pharmaceuticals Receives Positive Feedback from FDA (Aerie...

(Source: Aerie Pharmaceuticals Inc) -Rocket 2 Primary Endpoint Range Modified upon FDA Agreement- Conference Call and Webcast Today, June 15, at 5:00 p.m. ET IRVINE, Calif.--(BUSINESS WIRE)-- Aerie...

View Article


Aerie Pharmaceuticals Receives Positive Feedback from FDA

IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...

View Article

BioMarin Announces FDA Accepts Drisapersen NDA for Treatment of Duchenne...

(Source: BioMarin Pharmaceutical Inc) FDA Grants Priority Review Status FDA PDUFA Date is December 27, 2015 SAN RAFAEL, Calif., June 29, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc....

View Article

Vitae Pharmaceuticals Announces Top-Line Results From Metformin Arm of...

FORT WASHINGTON, Pa., June 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced top-line clinical efficacy results from the...

View Article

Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for...

- First Primary Biliary Cirrhosis Medication Submitted for Regulatory Review in Nearly Two Decades - NEW YORK, June 29, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT)...

View Article



Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for...

(Source: Intercept Pharmaceuticals Inc) NEW YORK, June 29, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the...

View Article

Aerie Pharmaceuticals Elects Julie McHugh and Michael M. du Toit to the...

IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (the "Company"), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of...

View Article

Aerie Pharmaceuticals Elects Julie McHugh and Michael M. du Toit to the...

(Source: Aerie Pharmaceuticals Inc) IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (the "Company"), a clinical-stage pharmaceutical company focused on the discovery,...

View Article

Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2015 Healthcare...

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Cantor Fitzgerald Inaugural “From Bench...

View Article


Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2015 Healthcare...

(Source: Aerie Pharmaceuticals Inc) IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) today announced that Vicente...

View Article

Tobira Therapeutics Announces Appointment of Ian Clements as Vice President,...

(Source: Tobira Therapeutics Inc) SOUTH SAN FRANCISCO, Calif., June 23, 2015 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the...

View Article

U.S. FDA Grants Priority Review for MM-398 New Drug Application (Merrimack...

(Source: Merrimack Pharmaceuticals Inc) CAMBRIDGE, Mass. and DEERFIELD, Ill., June 25, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) and Baxalta Incorporated, a wholly-owned...

View Article


Evotec's Partner Roche Provides Initial Update From Phase IIb Trial in...

HAMBURG, Germany, June 30, 2015 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) was updated today by its partner Roche (SIX:RO) (SIX:ROG) (OTCQX:RHHBY) on the initial results...

View Article


Catabasis Pharmaceuticals Initiates MoveDMD, a Phase 1/2 Trial of CAT-1004...

(Source: Catabasis Pharmaceuticals Inc) FOR IMMEDIATE RELEASE Catabasis Pharmaceuticals Initiates MoveDMD, a Phase 1/2 Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy CAMBRIDGE, MA,...

View Article

Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin™ for...

SAN JOSE, Calif., June 30, 2015 /PRNewswire/ -- Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced...

View Article
Browsing latest articles
Browse All 57 View Live




Latest Images